TY - JOUR
T1 - Hyperbaric Oxygen Therapy for Veterans With Treatment-resistant PTSD
T2 - A Longitudinal Follow-up Study
AU - Doenyas-Barak, Keren
AU - Kutz, Ilan
AU - Levi, Gabriela
AU - Lang, Erez
AU - Beberashvili, Ilia
AU - Efrati, Shai
N1 - Publisher Copyright:
© The Association of Military Surgeons of the United States 2022.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Introduction: PTSD is common among veteran combatants. PTSD is characterized by brain changes, for which available treatments have shown limited effect. In a short-term study, we showed that hyperbaric oxygen therapy (HBOT) induced neuroplasticity and improved clinical symptoms of veterans with treatment-resistant PTSD. Here, we evaluated the long-term clinical symptoms of the participants of that study. Materials and Methods: Veterans from our short-term study were recruited 1 or more years after completing HBOT. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and self-reported questionnaires were administered at a single site visit. Changes in clinical scores between long-term, short-term, and pretreatment evaluations were analyzed. Results: Of the 28 participants who received HBOT during or following the short-term study, 22 agreed to participate in the current study. At a mean of 704 ± 230 days after completing the HBOT course, the mean CAPS-5 score (26.6 ± 14.4) was significantly better (lower) than at the pre-HBOT evaluation (47.5 ± 13.1, P< .001) and not statistically different from the short-term evaluation (28.6 ± 16.7, P = .745). However, for the CAPS-5 subcategory D (cognition and mood symptoms), the mean score was significantly better (lower) at long-term than at short-term evaluation (7.6 ± 5.1 vs. 10.0 ± 6.0, P< .001). At the long-term compared to the pretreatment evaluation, higher proportions of the participants were living with life partners (10 (46%) vs. 17 (77%), P = .011) and were working (9 (41%) vs. 16 (73%), P = .033). Decreases were observed between pretreatment and the long-term follow-up, in the number of benzodiazepine users (from 10 (46%) to 4 (18%), P = .07) and in the median (range) cannabis daily dose (from 40.0 g (0-50) to 22.5 g (0-30), P =.046). Conclusions: The beneficial clinical effects of HBOT are persistent and were not attenuated at long-term follow-up of about 2years after completion of HBOT. Additional long-term effects of the treatment were observed in social function and in decreased medication use.
AB - Introduction: PTSD is common among veteran combatants. PTSD is characterized by brain changes, for which available treatments have shown limited effect. In a short-term study, we showed that hyperbaric oxygen therapy (HBOT) induced neuroplasticity and improved clinical symptoms of veterans with treatment-resistant PTSD. Here, we evaluated the long-term clinical symptoms of the participants of that study. Materials and Methods: Veterans from our short-term study were recruited 1 or more years after completing HBOT. The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and self-reported questionnaires were administered at a single site visit. Changes in clinical scores between long-term, short-term, and pretreatment evaluations were analyzed. Results: Of the 28 participants who received HBOT during or following the short-term study, 22 agreed to participate in the current study. At a mean of 704 ± 230 days after completing the HBOT course, the mean CAPS-5 score (26.6 ± 14.4) was significantly better (lower) than at the pre-HBOT evaluation (47.5 ± 13.1, P< .001) and not statistically different from the short-term evaluation (28.6 ± 16.7, P = .745). However, for the CAPS-5 subcategory D (cognition and mood symptoms), the mean score was significantly better (lower) at long-term than at short-term evaluation (7.6 ± 5.1 vs. 10.0 ± 6.0, P< .001). At the long-term compared to the pretreatment evaluation, higher proportions of the participants were living with life partners (10 (46%) vs. 17 (77%), P = .011) and were working (9 (41%) vs. 16 (73%), P = .033). Decreases were observed between pretreatment and the long-term follow-up, in the number of benzodiazepine users (from 10 (46%) to 4 (18%), P = .07) and in the median (range) cannabis daily dose (from 40.0 g (0-50) to 22.5 g (0-30), P =.046). Conclusions: The beneficial clinical effects of HBOT are persistent and were not attenuated at long-term follow-up of about 2years after completion of HBOT. Additional long-term effects of the treatment were observed in social function and in decreased medication use.
UR - http://www.scopus.com/inward/record.url?scp=85176009423&partnerID=8YFLogxK
U2 - 10.1093/milmed/usac360
DO - 10.1093/milmed/usac360
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 36433746
AN - SCOPUS:85176009423
SN - 0026-4075
VL - 188
SP - E2227-E2233
JO - Military Medicine
JF - Military Medicine
IS - 7-8
ER -